Research Reports

Key takeaways

Revenue grew 72.5% YoY to $2.4M, driven by OneRF product sales to Zimmer.

Gross margin was 53.8%, down from the prior period due to higher component costs and a lower average selling price from sales mix.

Operating loss improved 21.6% to -$2.1M, benefiting from lower legal and professional fees.

Net loss narrowed 8.1% to -$2.1M, but diluted EPS worsened to -$0.25 from -$0.07 due to increased share count.

Cash used in operations was -$4.4M, leading to free cash flow of -$4.5M, reflecting higher working capital needs.

Management noted that if additional funds are not raised, planned expenditures may need to be reduced to extend the runway.

Full analysis

Revenue Growth Driven by OneRF Sales

Revenue for the second quarter of fiscal 2026 increased 72.5% to $2.4 million from $1.4 million in the prior-year quarter, primarily driven by sales of OneRF products to Zimmer Biomet. This growth reflects continued adoption of the company's technology in the neuromodulation market.

Gross Margin Compression on Cost and Mix

Operating Loss Narrows on Cost Discipline

Cash Burn Intensifies; Going Concern Risk Remains

Outlook and Strategic Focus

Management anticipates that selling, general and administrative expenses will increase in the future to support continued research and development, further commercialization of the technology, and the increased costs of operating as a public company. The company continues to assess its liquidity needs and may seek additional financing through equity or debt offerings.

NMTC · NeuroOne Medical Technologies Corporation